Orchard Announces Publication by San Raffaele-Telethon Institute for Gene Therapy of OTL-300 Clinical Data for the Treatment of Transfusion-Dependent Beta-Thalassemia in Nature Medicine
January 22, 2019 07:30 ET
|
Orchard Therapeutics
BOSTON and LONDON, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics Highlights Recent Accomplishments and 2019 Strategic Priorities as a Global Leader in Gene Therapy
January 07, 2019 08:00 ET
|
Orchard Therapeutics
Preparing Three Lead Programs for MLD, ADA-SCID and WAS for Regulatory Filings Over the Next Three Years Recently Announced Clinical Proof-of-Concept in X-CGD Demonstrates Platform’s Transformative...
Orchard Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019
January 02, 2019 16:01 ET
|
Orchard Therapeutics
BOSTON and LONDON, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics and SIRION Biotech Announce Licensing Agreement to Enhance Gene Therapy Manufacturing Efficiency
December 14, 2018 07:30 ET
|
Orchard Therapeutics
BOSTON and LONDON and MARTINSRIED, Germany, Dec. 14, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the...
Orchard Therapeutics Announces the Build-out of New Gene Therapy Manufacturing Facility in California
December 13, 2018 07:30 ET
|
Orchard Therapeutics
New facility expected to create more than 100 new jobs, supporting extensive gene therapy pipeline Enhances Orchard’s capacity to develop and deliver lentiviral vector and gene-corrected hematopoetic...
Donald B. Kohn, MD, Orchard Therapeutics Scientific Advisory Board Member, Presents Clinical Proof-of-Concept Data for OTL-102 Gene Therapy for the Treatment of Patients with X-CGD at the Presidential Symposium at the 2018 ASH Annual Meeting
December 05, 2018 07:30 ET
|
Orchard Therapeutics
BOSTON and LONDON, Dec. 05, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of...
Orchard Therapeutics Strengthens Global Commercial Leadership Team with Appointments of Heads of US and EMEA Region Commercial Operations
November 08, 2018 07:30 ET
|
Orchard Therapeutics
Commercial team preparing for potential gene therapy launches BOSTON and LONDON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a leading commercial-stage biotech company dedicated to...
Orchard Therapeutics Announces Closing of $225 Million Initial Public Offering, Including the Partial Exercise of Underwriters’ Option
November 05, 2018 07:00 ET
|
Orchard Therapeutics
BOSTON and LONDON, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics plc (Nasdaq: ORTX), a biopharmaceutical company dedicated to transforming the lives of patients with serious and...
Orchard Therapeutics Announces Pricing of Initial Public Offering
October 30, 2018 22:21 ET
|
Orchard Therapeutics
BOSTON and LONDON, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics plc (Nasdaq: ORTX), a biopharmaceutical company dedicated to transforming the lives of patients with serious and...
Orchard Therapeutics Receives EMA PRIME Designation for OTL-300, an Investigational Lentiviral Gene Therapy for the Treatment of Transfusion-Dependent Beta-Thalassemia
October 04, 2018 08:00 ET
|
Orchard Therapeutics
BOSTON and LONDON, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a leading commercial-stage biotech company dedicated to transforming the lives of patients with rare diseases through...